Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Cerilliant
Citi
AstraZeneca
Farmers Insurance
Federal Trade Commission
Fuji
Cipla
Johnson and Johnson
Colorcon

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,796,307

« Back to Dashboard

Which drugs does patent 8,796,307 protect, and when does it expire?


Patent 8,796,307 protects UTIBRON and ARCAPTA NEOHALER and is included in two NDAs.

This patent has forty-three patent family members in thirty-three countries.

Summary for Patent: 8,796,307

Title:Beta2-adrenoreceptor agonists
Abstract: Compounds of formula ##STR00001## in free or salt or solvate form, where Ar is a group of formula ##STR00002## Y is carbon or nitrogen and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
Inventor(s): Cuenoud; Bernard (Horsham, GB), Bruce; Ian (Horsham, GB), Fairhurst; Robin Alec (Horsham, GB), Beattie; David (Horsham, GB)
Assignee: Novartis AG (Basel, CH)
Application Number:14/076,478
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sunovion Pharms Inc
UTIBRON
glycopyrrolate ; indacaterol maleate
POWDER;INHALATION207930-001Oct 29, 2015RXYesYes► Subscribe► SubscribeY
Sunovion Pharms Inc
ARCAPTA NEOHALER
indacaterol maleate
POWDER;INHALATION022383-001Jul 1, 2011RXYesYes► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,796,307

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9913083.3Apr 6, 1999

Non-Orange Book Patents for Patent: 8,796,307

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,283,362Beta-2-adrenoreceptor agonists► Subscribe
6,878,721 Beta2-adrenoceptor agonists► Subscribe
9,040,559BETA2-adrenoceptor agonists► Subscribe
7,820,694Beta-2-adrenoreceptor agonists► Subscribe
8,067,437Beta-2-adrenoreceptor agonists► Subscribe
8,436,017Beta-2-adrenoreceptor agonists► Subscribe
7,622,483.beta.2-adrenoceptor agonists► Subscribe
8,658,673BETA2-adrenoreceptor agonists► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,796,307

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI253447► Subscribe
Turkey200103497► Subscribe
Slovakia287260► Subscribe
Slovakia17432001► Subscribe
Slovenia1183240► Subscribe
Russian Federation2244709► Subscribe
Portugal2332915► Subscribe
Portugal1183240► Subscribe
Poland198847► Subscribe
Poland352100► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Daiichi Sankyo
Argus Health
Medtronic
Chubb
US Department of Justice
QuintilesIMS
Citi
Federal Trade Commission
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot